ATE464299T1 - Neues phenylalaninderivat - Google Patents
Neues phenylalaninderivatInfo
- Publication number
- ATE464299T1 ATE464299T1 AT03705344T AT03705344T ATE464299T1 AT E464299 T1 ATE464299 T1 AT E464299T1 AT 03705344 T AT03705344 T AT 03705344T AT 03705344 T AT03705344 T AT 03705344T AT E464299 T1 ATE464299 T1 AT E464299T1
- Authority
- AT
- Austria
- Prior art keywords
- phenylalanine derivative
- new phenylalanine
- integrin
- alpha
- new
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
- C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
- C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D265/24—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in positions 2 and 4
- C07D265/26—Two oxygen atoms, e.g. isatoic anhydride
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/80—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
- C07D239/96—Two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
- C07D253/04—1,2,3-Triazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/15—Six-membered rings
- C07D285/16—Thiadiazines; Hydrogenated thiadiazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/15—Six-membered rings
- C07D285/16—Thiadiazines; Hydrogenated thiadiazines
- C07D285/18—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines
- C07D285/20—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems
- C07D285/22—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D285/24—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002043674 | 2002-02-20 | ||
PCT/JP2003/001852 WO2003070709A1 (fr) | 2002-02-20 | 2003-02-20 | Nouveau derive de phenylalanine |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE464299T1 true ATE464299T1 (de) | 2010-04-15 |
Family
ID=27750531
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT03705344T ATE464299T1 (de) | 2002-02-20 | 2003-02-20 | Neues phenylalaninderivat |
Country Status (7)
Country | Link |
---|---|
US (1) | US7605165B2 (de) |
EP (1) | EP1477482B1 (de) |
JP (1) | JP4470219B2 (de) |
AT (1) | ATE464299T1 (de) |
AU (1) | AU2003211560A1 (de) |
DE (1) | DE60332093D1 (de) |
WO (1) | WO2003070709A1 (de) |
Families Citing this family (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU7874001A (en) | 2000-08-18 | 2002-03-04 | Ajinomoto Kk | Novel phenylalanine derivatives |
JP4452899B2 (ja) * | 2001-12-13 | 2010-04-21 | 味の素株式会社 | 新規フェニルアラニン誘導体 |
DK1558585T3 (da) | 2002-10-04 | 2014-01-06 | Prana Biotechnology Ltd | Neurologisk aktive forbindelser |
CN101386600B (zh) * | 2003-02-20 | 2011-07-06 | 味之素株式会社 | 具有喹唑二酮骨架的苯丙氨酸衍生物的制造方法及制造中间体 |
JP4947482B2 (ja) * | 2003-11-14 | 2012-06-06 | 味の素株式会社 | フェニルアラニン誘導体の徐放性経口投与製剤 |
WO2005051925A1 (ja) * | 2003-11-27 | 2005-06-09 | Ajinomoto Co., Inc. | フェニルアラニン誘導体の結晶及びその製造方法 |
AU2004303696B2 (en) * | 2003-12-22 | 2011-03-31 | Ea Pharma Co., Ltd. | Novel phenylalanine derivative |
US7618981B2 (en) * | 2004-05-06 | 2009-11-17 | Cytokinetics, Inc. | Imidazopyridinyl-benzamide anti-cancer agents |
CN102512675A (zh) | 2004-06-04 | 2012-06-27 | 健泰科生物技术公司 | 用于治疗多发性硬化的方法 |
KR20080024536A (ko) | 2005-06-21 | 2008-03-18 | 아지노모토 가부시키가이샤 | 페닐알라닌 유도체의 결정, 이의 제조방법 및 이의 용도 |
MY149159A (en) | 2005-11-15 | 2013-07-31 | Hoffmann La Roche | Method for treating joint damage |
CN101360736A (zh) * | 2005-11-23 | 2009-02-04 | 阿斯利康(瑞典)有限公司 | L-丙氨酸衍生物 |
NZ568946A (en) * | 2005-12-29 | 2010-07-30 | Lexicon Pharmaceuticals Inc | Multicyclic amino acid derivatives and methods of their use |
EP2514423A3 (de) | 2006-04-14 | 2012-12-19 | Prana Biotechnology Ltd | Verfahren zur Behandlung von altersbedingter Makuladegeneration (AMD) |
WO2007141473A1 (en) * | 2006-06-09 | 2007-12-13 | Astrazeneca Ab | N-(benzoyl)-o- [2- (pyridin- 2 -ylamino) ethyl] -l-tyrosine derivatives and related compounds as a5b1 antagonists for the treatment of solid tumors |
JP5136413B2 (ja) * | 2006-06-20 | 2013-02-06 | 東レ株式会社 | 白血病の治療又は予防剤 |
WO2008064823A1 (en) * | 2006-11-27 | 2008-06-05 | Ucb Pharma, S.A. | Bicyclic and heterobicyclic derivatives, processes for preparing them and their uses |
WO2008073958A2 (en) | 2006-12-12 | 2008-06-19 | Wyeth | Substituted benzothiadiazinedioxide derivatives and methods of their use |
WO2008093065A1 (en) * | 2007-01-29 | 2008-08-07 | Astrazeneca Ab | L-ALANINE DERIVATIVES AS α5βL ANTAGONISTS |
WO2008125811A1 (en) * | 2007-04-11 | 2008-10-23 | Astrazeneca Ab | N-[HETEROARYLCARBONYL]-S-THIENYL-L-ALANINE DERIVATIVES AS α5β1 ANTAGONISTS |
WO2008138592A1 (en) * | 2007-05-14 | 2008-11-20 | Ucb Pharma, S.A. | Bicyclic and heterobicyclic derivatives, processes for preparing them and their uses |
PL2334378T3 (pl) | 2008-08-19 | 2014-09-30 | Xenoport Inc | Proleki wodorofumaranu metylu, ich kompozycje farmaceutyczne i sposoby zastosowania |
AR073295A1 (es) | 2008-09-16 | 2010-10-28 | Genentech Inc | Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion. |
WO2010075249A2 (en) | 2008-12-22 | 2010-07-01 | Genentech, Inc. | A method for treating rheumatoid arthritis with b-cell antagonists |
JP2013510092A (ja) * | 2009-11-05 | 2013-03-21 | レクシコン ファーマシューティカルズ インコーポレイテッド | がんの治療のためのトリプトファンヒドロキシラーゼ阻害剤 |
WO2011094890A1 (en) * | 2010-02-02 | 2011-08-11 | Argusina Inc. | Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators |
EP2579888A2 (de) | 2010-06-09 | 2013-04-17 | Receptos, Inc. | Neue glp-1-rezeptor-stabilisatoren und -modulatoren |
PT2713722T (pt) | 2011-05-31 | 2017-06-27 | Receptos Llc | Novos estabilizadores e moduladores do receptor glp-1 |
KR20140107340A (ko) * | 2011-12-12 | 2014-09-04 | 레셉토스, 인코포레이티드 | 당뇨병과 같은 치료를 위한 glp-1 수용체 조절제로서 작용하는 4 개의 사이클을 포함하는 카르복실산 유도체 |
WO2013101771A2 (en) | 2011-12-30 | 2013-07-04 | Genentech, Inc. | Compositions and method for treating autoimmune diseases |
BR112014018471A2 (pt) | 2012-01-31 | 2017-07-04 | Genentech Inc | anticorpos anti-ige m1' e métodos para o seu uso |
KR101698796B1 (ko) | 2012-04-24 | 2017-01-23 | 이에이 파마 가부시키가이샤 | 설폰아미드 유도체 및 이의 의약 용도 |
JP2015519371A (ja) * | 2012-05-30 | 2015-07-09 | ゼノポート,インコーポレイティド | フマル酸水素メチルのプロドラッグを用いた多発性硬化症及び乾癬の治療 |
US10945984B2 (en) | 2012-08-22 | 2021-03-16 | Arbor Pharmaceuticals, Llc | Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects |
AU2013305684B2 (en) | 2012-08-22 | 2016-11-24 | Xenoport, Inc. | Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof |
US8669281B1 (en) | 2013-03-14 | 2014-03-11 | Alkermes Pharma Ireland Limited | Prodrugs of fumarates and their use in treating various diseases |
ES2955137T3 (es) | 2013-03-14 | 2023-11-28 | Alkermes Pharma Ireland Ltd | Profármacos de fumaratos y su uso en el tratamiento de diversas enfermedades |
US10179118B2 (en) | 2013-03-24 | 2019-01-15 | Arbor Pharmaceuticals, Llc | Pharmaceutical compositions of dimethyl fumarate |
WO2014197860A1 (en) | 2013-06-07 | 2014-12-11 | Xenoport, Inc. | Method of making monomethyl fumarate |
BR112015031040A8 (pt) * | 2013-06-11 | 2018-01-02 | Receptos Inc | Novos moduladores do receptor de glp-1 |
WO2014205392A1 (en) | 2013-06-21 | 2014-12-24 | Xenoport, Inc. | Cocrystals of dimethyl fumarate |
JP2016534133A (ja) | 2013-09-06 | 2016-11-04 | ゼノポート,インコーポレイティド | (n,n−ジエチルカルバモイル)メチル メチル(2e)ブト−2−エン−1,4−ジオエートの結晶形態、その合成方法及び使用 |
KR101806103B1 (ko) | 2013-10-29 | 2017-12-07 | 이에이 파마 가부시키가이샤 | 설폰아미드 유도체 및 이의 의약 용도 |
NZ723269A (en) | 2014-02-24 | 2017-04-28 | Alkermes Pharma Ireland Ltd | Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases |
US9999672B2 (en) | 2014-03-24 | 2018-06-19 | Xenoport, Inc. | Pharmaceutical compositions of fumaric acid esters |
MX2017000972A (es) | 2014-07-25 | 2017-07-27 | Celgene Int Ii Sarl | Nuevos moduladores del receptor de peptido similar a glucagon 1 (glp-1). |
JP2017538711A (ja) * | 2014-12-10 | 2017-12-28 | セルジーン インターナショナル ツー エスエーアールエル | Glp−1レセプターモジュレーター |
IL293708A (en) | 2015-10-06 | 2022-08-01 | Genentech Inc | A method for treating multiple sclerosis |
HUE053354T2 (hu) | 2016-02-05 | 2021-06-28 | Ea Pharma Co Ltd | Szulfonamid-származékok és ezeket tartalmazó gyógyászati készítmények |
CA3115820A1 (en) | 2018-10-30 | 2020-05-07 | Gilead Sciences, Inc. | Compounds for inhibition of .alpha.4.beta.7 integrin |
CN112969504B (zh) | 2018-10-30 | 2024-04-09 | 吉利德科学公司 | 用于抑制α4β7整合素的化合物 |
CA3114240C (en) | 2018-10-30 | 2023-09-05 | Gilead Sciences, Inc. | Imidazopyridine derivatives as alpha4beta7 integrin inhibitors |
BR112021007213A2 (pt) | 2018-10-30 | 2021-08-10 | Gilead Sciences, Inc. | derivados de quinolina como inibidores de integrina alfa4beta7 |
AU2020329207B2 (en) | 2019-08-14 | 2024-02-29 | Gilead Sciences, Inc. | Compounds for inhibition of alpha 4 beta 7 integrin |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2102009T5 (es) | 1992-01-13 | 2004-12-16 | Biogen Inc | Tratamiento para el asma. |
ES2103468T3 (es) | 1992-02-12 | 1997-09-16 | Biogen Inc | Tratamiento de la inflamacion intestinal. |
WO1994015958A2 (en) | 1993-01-08 | 1994-07-21 | Tanabe Seiyaku Co., Ltd. | Peptide inhibitors of cell adhesion |
JPH08507680A (ja) | 1993-01-12 | 1996-08-20 | バイオジェン インコーポレイテッド | 組換え抗vla4抗体分子 |
AU693143B2 (en) | 1993-12-06 | 1998-06-25 | Cytel Corporation | CS-1 peptidomimetics, compositions and methods of using the same |
SE502501C2 (sv) | 1993-12-07 | 1995-10-30 | Ulf Malmgren | Anordning för fallskyddad klättring |
JPH10502349A (ja) | 1994-06-29 | 1998-03-03 | テキサス・バイオテクノロジー・コーポレイシヨン | インテグリンα▲下4▼β▲下1▼のVCAM−1またはフィブロネクチンへの結合を阻害する方法 |
US5811391A (en) | 1994-08-25 | 1998-09-22 | Cytel Corporation | Cyclic CS-1 peptidomimetics, compositions and methods of using same |
JP2001512139A (ja) * | 1997-07-31 | 2001-08-21 | エラン・ファーマシューティカルズ・インコーポレーテッド | Vla−4が介在する白血球接着を阻害するスルホニル化ジペプチド化合物 |
ATE260243T1 (de) | 1997-08-22 | 2004-03-15 | Hoffmann La Roche | N-aroylphenylalaninderivate |
DE69824183T2 (de) | 1997-08-22 | 2005-04-21 | Hoffmann La Roche | N-alkanoylphenylalaninderivate |
MY153569A (en) | 1998-01-20 | 2015-02-27 | Mitsubishi Tanabe Pharma Corp | Inhibitors of ?4 mediated cell adhesion |
US6329372B1 (en) | 1998-01-27 | 2001-12-11 | Celltech Therapeutics Limited | Phenylalanine derivatives |
US6555562B1 (en) | 1998-02-26 | 2003-04-29 | Celltech R&D Limited | Phenylalanine derivatives |
WO2001036376A1 (fr) * | 1999-11-18 | 2001-05-25 | Ajinomoto Co., Inc. | Nouveaux dérivés de la phénylalanine |
WO2001047868A1 (fr) | 1999-12-28 | 2001-07-05 | Ajinomoto Co., Inc. | Nouveaux derives de phenylalanine |
AU7874001A (en) * | 2000-08-18 | 2002-03-04 | Ajinomoto Kk | Novel phenylalanine derivatives |
CN101386600B (zh) | 2003-02-20 | 2011-07-06 | 味之素株式会社 | 具有喹唑二酮骨架的苯丙氨酸衍生物的制造方法及制造中间体 |
WO2005046696A1 (ja) * | 2003-11-14 | 2005-05-26 | Ajinomoto Co., Inc. | フェニルアラニン誘導体の固体分散体または固体分散体医薬製剤 |
WO2005051925A1 (ja) | 2003-11-27 | 2005-06-09 | Ajinomoto Co., Inc. | フェニルアラニン誘導体の結晶及びその製造方法 |
AU2004303696B2 (en) * | 2003-12-22 | 2011-03-31 | Ea Pharma Co., Ltd. | Novel phenylalanine derivative |
-
2003
- 2003-02-20 WO PCT/JP2003/001852 patent/WO2003070709A1/ja active Application Filing
- 2003-02-20 JP JP2003569616A patent/JP4470219B2/ja not_active Expired - Fee Related
- 2003-02-20 EP EP03705344A patent/EP1477482B1/de not_active Expired - Lifetime
- 2003-02-20 AU AU2003211560A patent/AU2003211560A1/en not_active Abandoned
- 2003-02-20 AT AT03705344T patent/ATE464299T1/de not_active IP Right Cessation
- 2003-02-20 DE DE60332093T patent/DE60332093D1/de not_active Expired - Lifetime
-
2004
- 2004-08-20 US US10/921,929 patent/US7605165B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
DE60332093D1 (de) | 2010-05-27 |
EP1477482A1 (de) | 2004-11-17 |
US7605165B2 (en) | 2009-10-20 |
AU2003211560A1 (en) | 2003-09-09 |
EP1477482B1 (de) | 2010-04-14 |
EP1477482A4 (de) | 2006-03-15 |
US20050101779A1 (en) | 2005-05-12 |
JPWO2003070709A1 (ja) | 2005-06-09 |
JP4470219B2 (ja) | 2010-06-02 |
WO2003070709A1 (fr) | 2003-08-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE464299T1 (de) | Neues phenylalaninderivat | |
MXPA03001495A (es) | Derivados de fenilalanina novedosos. | |
ATE355269T1 (de) | Phenylalaninderivate | |
FR18C1024I1 (fr) | Derives d'heterocyclocarboxamide | |
FR20C1039I2 (fr) | Derives de l'uk-2a | |
EA200100678A1 (ru) | N-уреидоалкил-пиперидины в качестве модуляторов активности рецепторов хемокинов | |
ATE341537T1 (de) | Dolastatin 10 derivate | |
EP2615087A3 (de) | Phenylalaninderivate | |
DK1572229T3 (da) | Stabilt terapeutisk fibrinogen | |
NO20054662D0 (no) | Farmasoytisk sammensetning omfattende 5-metyl-2-2'-(klor-6'-fluoranilin)fenyleddiksyre | |
IL164836A0 (en) | Phosphonates and derivatives thereof as enhancers of the activity of insecticides | |
MA27240A1 (fr) | Derives d'imidazoquinoleine | |
ITPD20020251A1 (it) | Dispositivo per l'ottimizzazione dell'innesto di | |
DE60336549D1 (de) | Hepatoprotektor aktivität von 2'-p-hydroxybenzoylmussaenosidsäure | |
DE50310743D1 (de) | Wässrige formulierungen von (2-hydroxymethyl-indanyl-4-oxy)-phenyl-4,4,4- trifluorbutan-1-sulfonat | |
ITMI20021277A1 (it) | Perfluoropolieteri comprendenti unita' ripetitive ottenute dall'ossidazione di perfluorodiossoli | |
FR2845116B1 (fr) | Chassis d'ouvrant respirant | |
FR2834894B1 (fr) | Composition pharmaceutique orodispersible de piribedil | |
ITPI20020047A1 (it) | "sostegno sagomato per scarpe" | |
ITRC20020003U1 (it) | "fragrant shoe - scarpa profumata" | |
ITRC20020006A1 (it) | "fragrant shoe - scarpa profumata" | |
IT1317883B1 (it) | Modello di arcata dentaria almeno parzialmente edentula per provepreventive ad operazioni chirurgiche volte all'installazione di | |
ITLU20020007U1 (it) | "calendario-libro" | |
ITMI20022594A1 (it) | Combinazione terapeutica per la cura dell'ipertensione. | |
ECSP972236A (es) | Derivados de 6,6- heterobiciclicos sustituidos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |